PROTAC EGFR degrader 10 is a small molecule designed to selectively degrade the epidermal growth factor receptor (EGFR), which is often implicated in various cancers. This compound belongs to a class of molecules known as PROTACs (Proteolysis Targeting Chimeras), which harness the cell's ubiquitin-proteasome system to promote the degradation of specific proteins. The structure of PROTAC EGFR degrader 10 typically includes a ligand that binds to EGFR and another that recruits an E3 ubiquitin ligase, facilitating the ubiquitination and subsequent degradation of the target protein. This targeted approach aims to reduce the levels of EGFR in cancer cells, potentially overcoming resistance to traditional EGFR inhibitors. The compound is characterized by its ability to induce selective protein degradation, which can lead to enhanced therapeutic efficacy and reduced side effects compared to conventional small molecule inhibitors. Research into PROTACs like this one is ongoing, with the goal of developing more effective cancer treatments that can address the limitations of existing therapies.

PROTAC EGFR degrader 10

3034244-56-6: PROTAC EGFR degrader 10 is a small molecule designed to selectively degrade the epidermal growth factor receptor (EGFR), which is often implicated in various cancers. This compound belongs to a class of molecules known as PROTACs (Proteolysis Targeting Chimeras), which harness the cell's ubiquitin-proteasome system to promote the degradation of specific proteins. The structure of PROTAC EGFR degrader 10 typically includes a ligand that binds to EGFR and another that recruits an E3 ubiquitin ligase, facilitating the ubiquitination and subsequent degradation of the target protein. This targeted approach aims to reduce the levels of EGFR in cancer cells, potentially overcoming resistance to traditional EGFR inhibitors. The compound is characterized by its ability to induce selective protein degradation, which can lead to enhanced therapeutic efficacy and reduced side effects compared to conventional small molecule inhibitors. Research into PROTACs like this one is ongoing, with the goal of developing more effective cancer treatments that can address the limitations of existing therapies.

<p>PROTAC EGF Rdegrader 10 (Compound B56) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR) with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 37 nM and degrades EGFR, focal adhesion kinase (FAK), and RSK1, inhibiting the proliferation of BaF3 wild-type and EGFR mutants with an IC50 of less than 150 nM.</p>

CAS 3034244-56-6

PROTAC EGFR degrader 10

PROTAC EGFR degrader 10

Ref: TM-T88273